Anthropic embraces “Pipeline-in-a-Person”

Cody Tranbarger’s Claude-driven biotech joins AI giant.

Cody Tranbarger, better known on social media as Professor Oak, has stepped out of anonymity by announcing that Anthropic has acquired his one-person biotech startup, Mithril Medicine. Founded just 18 months ago, Mithril was built around a radical model: a single operator supported by Anthropic’s Claude AI and part-time consultants. This unconventional setup produced promising early results in developing treatments for rare muscle disorders, particularly LAMA2 congenital muscular dystrophy.

Tranbarger revealed that Mithril’s lean structure let him test how far drug discovery could scale with one person working alongside advanced AI. Within a year and a half, the company achieved proof of principle in mice, showing improved muscle strength with antibody-based therapies. Although the experiments await peer review and were not randomized, the process’s speed and efficiency demonstrated the potential of AI-assisted biotech. Anthropic has indicated that, if the results hold, clinical trials could begin as early as 2028.

The acquisition represents more than just additional resources for Mithril’s programs. For Tranbarger, it offers the rare opportunity to run multiple drug pipelines simultaneously, a luxury he describes as transformative for drug hunters. His vision, dubbed “Pipeline-in-a-Person,” emphasizes parallelization and orchestration rather than simply accelerating timelines. By enabling scientists to manage several projects at once, he believes AI can improve decision-making, increase success rates, and ultimately expand patient impact.

Anthropic’s move fits into its broader strategy of applying AI to life sciences. The company has already partnered with organizations such as BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. These collaborations span molecule design, lead optimization, regulatory filings, and clinical trial planning. Mithril’s integration adds a new dimension: proof that even a single researcher, empowered by AI, can drive meaningful progress in drug development.

For Tranbarger, the journey from anonymous Twitter persona to biotech founder acquired by a leading AI company underscores both AI’s disruptive potential in medicine and the evolving nature of scientific entrepreneurship. Signing off his announcement with a playful nod to his online identity, he promised to continue sharing insights from the frontier of drug discovery: “Gotta Cure ’Em All.”